Comparison of two chemotherapy regimens including carboplatin-paclitaxel and capecitabine-oxaliplatin in neo-adjuvant chemo-radiation of esophageal cancer
Phase 2
Recruiting
- Conditions
- Esophageal cancer.Malignant neoplasm of lower third of esophagus
- Registration Number
- IRCT20140903019036N3
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 92
Inclusion Criteria
Tumor should located in thoracic esophagus or gastro-esophageal junction.
Patients' age should be between 18-75 years old.
Pathology consists of squamous cell carcinoma or adenocarcinoma.
Tumor should be resectable.
Disease should be curable.
Exclusion Criteria
Patient who suffers from bad performance status.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor regression grade. Timepoint: Tumor regression grade will determine once after surgery. Method of measurement: Tumor regression grade will determine through surgical sample by pathologist.
- Secondary Outcome Measures
Name Time Method Gastrointestinal adverse effects. Timepoint: Gastrointestinal adverse effects will be evaluated at 1 and 3 months after neo-adjuvant chemoradiation. Method of measurement: Gastrointestinal adverse effects will be evaluated through CTCAE (Common Terminology Criteria for Adverse Events).;Hematologic adverse effects. Timepoint: Hematologic adverse effects will be evaluated at 1 and 3 months after neo-adjuvant chemoradiation. Method of measurement: Hematologic adverse effects will be evaluated through CTCAE (Common Terminology Criteria for Adverse Events).;Surgical margin's tumor remnant. Timepoint: Surgical margin's tumor remnant is determined once after surgery. Method of measurement: Surgical margin's tumor remnant is determined through pathologist's assessment.